Information Provided By:
Fly News Breaks for May 3, 2018
ESPR
May 3, 2018 | 08:36 EDT
Citi analyst Joel Beatty lowered his price target for Esperion to $57 from $96 and keeps a Neutral rating on the shares. Yesterday's Phase 3 data for bempedoic acid adds risk and makes a takeover of Esperion unlikely in the near-term, Beatty tells investors in a research note. He continues to believe that bempedoic acid is likely to get approved and be used in a niche of patients who prefer to take an oral pill daily. The analyst sees potential upside for the shares if additional granularity is provided on the Phase 3 trials to date.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.